Committed to babies and their health
Clinically proven to improve health outcomes of critically ill preemies
Committed to scientific and clinical research in breast milk
Prolact Product Safety

Board of Directors



John Bacich Jr.

Chairman of the Board

Mr. Bacich has been involved in the biopharmaceutical industry for 40 years. Most of that experience was with Baxter Healthcare beginning in 1968 and retiring in 1998. He held a variety of positions including quality management, research and development, global manufacturing operations, and general management leading to the presidency of what is now called the Bioscience Division of Baxter Healthcare.

In his capacity as president he was responsible for the plasma products worldwide and the development of the recombinant proteins business. He was also a charter board member of the Plasma Protein Therapeutics Association which is the only industry association for plasma products producers and their recombinant equivalents.

Mr. Bacich remains active in the industry as a consultant and is a member of the EMT for Inspiration Biopharmaceuticals. He is also a past director of the Southern California Hemophilia Society. Mr. Bacich holds a BS in Microbiology from California State University at Long Beach.

David Brailer, Prolacta Board Member
David Brailer
Board Member

David Brailer

Board Member

David founded the health information technology program at The Wharton School of Business, with in the University of Pennsylvania. He also taught health management and economics in their MBA program and lectured in The Wharton Executive Education Program. David was also an active patient-care physician in general medicine and in immune deficiency at the University of Pennsylvania.

David also founded CareScience as a spin out from The Wharton School and led it through several financings, strategic partnerships, an IPO and a strategic sale. Under David’s leadership, CareScience established itself as an early leader in the use of the internet to share health information and to improve the quality of care across the United States.

David was appointed the nation’s first National Coordinator for Health-Information Technology in May of 2004. In this role David was the architect of the nation’s effort to bring our health care system into the information age. David is now a managing partner and CEO at Health Evolution Partners, where he came aboard in 2007. David joined Prolacta Bioscience Board of Directors in 2014, and also sits on three other boards for CenseoHealth, Optimal Radiology and Walgreen Company.


Sally Crawford

Board Member

Sally Crawford has been a healthcare consultant in New Hampshire since 1997 working with health care providers, regulators, investors, employers and managed care payers on strategic marketing and reimbursement projects. From 1985 – 1997, Sally served as Chief Operating Officer of Healthsource, Inc., a publicly traded NYSE HMO and managed care company before it was acquired by CIGNA. As COO, Sally organized the development of the Company’s management, operating systems, marketing strategies and supported strategic alliances with physicians, employers, hospitals, insurers and other health care companies.

Sally currently serves on the Board of Directors of five health care companies, including Hologic, Inc. (NASDAQ: HOLX), Insulet Corporation (NASDAQ: PODD), Universal American (NYSE: UAM), Exact Sciences (NASDAQ: EXAS) and Zalicus, Inc (NASDAQ:ZLCS). Prior Board positions include Cytyc Corporation (NASDAQ: CYTC), Chittenden Corporation (NYSE: CHZ) and Harborside Healthcare (NYSE: HBR).

Sally earned a Bachelor’s degree from Smith College and a Master’s degree in Communications from Boston University.


Scott A. Elster

Chief Executive Officer

Mr. Elster has over 20 years of experience in the biosciences and financial sectors. His experience encompasses planning, finance and strategy development, supply chain, and operations. Most recently, Mr. Elster was director of operations and supply chain at Clinical Micro Sensors (CMS), a Motorola Company. There, Mr. Elster successfully prepared operations for the company's first commercial launch, including FDA approval of the GMP manufacturing facility. He led the quality control function, the manufacturing team, and operational strategy development. His team was also responsible for materials and inventory management, as well as distribution and warehousing.

For over 13 years at Baxter, Mr. Elster's management work was focused directly on plasma products worldwide. His roles included manager of strategic planning, business development, finance and strategy for the hyperimmune business unit, and director of global supply chain. Mr. Elster began his career at Deloitte and Touche as a financial statement auditor, and is a current board member and past chairman of the board for Monrovia Growers.

Mr. Elster received a Bachelor of Science degree from California State University, Northridge, and a Master of Business degree from the Anderson Graduate School of Management at University of California, Los Angeles.


Dan Janney

Board Member

Dan Janney joined Alta Partners immediately following the firm’s founding in 1996, and was a co-founder of the Alta BioPharma effort.

Mr. Janney focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. He is currently on the board of directors of a number of companies, including Alba Therapeutics, DiscoveRx, Lithera and ViroBay. In addition, he led Alta’s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.

Prior to joining Alta, Mr. Janney was a senior investment banker at Montgomery Securities, focusing on life sciences companies. He is also a member of the advisory board for the Rebecca and John Moores Cancer Center at University of California, San Diego.

Mr. Janney holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.

Braden Kelly headshot, is a broad member of Prolacta Bioscience

Braden Kelly

Board Member

Braden Kelly has spent his career as a private equity investor and strategic advisor to global growth companies with an emphasis on technology driven innovation. Mr. Kelly is currently a Partner at Health Evolution Partners, a San Francisco-based private equity firm focused on healthcare companies. He is also Chairman of the Board of Fair Isaac Corporation (NYSE: FICO), a leading analytics software company operating in over 80 countries.

Previously, Mr. Kelly served as a Partner and Managing Director of General Atlantic, a global private equity investment firm focused on growth investing with over $20 billion in assets under management. During his tenure, Mr. Kelly was founder and head of General Atlantic’s Silicon Valley office, originated and ran its global health care practice, and was a member of its investment committee. Prior to joining General Atlantic, Mr. Kelly worked in the Mergers, Acquisitions and Restructurings Department of the Investment Banking Division at Morgan Stanley & Co. Over the last 20 years, he has served in leadership roles on numerous public and private boards.

A native of Columbus, Ohio, Mr. Kelly graduated with highest honors from the University of Notre Dame and received a Bachelors of Business Administration degree in Finance and Business Economics.


Headshot of Jacqueline Kosecoff, PhD, board member of Prolacta Bioscience

Jacqueline Kosecoff, PhD

Board Member

Dr. Kosecoff is a seasoned corporate executive and board member with special depth of knowledge in health services and technology.

In the early part of her career, Dr. Kosecoff helped found and lead PE-back companies, including Value Health Sciences and Protocare. She went on to serve as Executive Vice President of PacifiCare with responsibility for its specialty businesses, including its PBM, the Medicare Part D Drug Program, PacifiCare Behavioral Health (PBH), PacifiCare Dental & Vision (PDV), and Women’s Health Solutions. Upon joining UnitedHealth Dr. Kosecoff was appointed CEO of Prescription Solutions (later renamed OptumRx) with responsibility for United’s PBM, Specialty Pharmacy and Consumer Health Products, providing services as of 2011 to more than 13 million members with annual revenue of $18.5 billion.

In addition to her accomplishments as an entrepreneur, Dr. Kosecoff is a recognized expert in the areas of clinical and health services research, quality of care and technology assessment, disease management, and organization of the health care delivery system.

Currently, Dr. Kosecoff is working in private equity to identify, select, mentor and manage health services and IT companies. She sits on the board of directors of these public companies: Houlihan Lokey (NYSE: HLI); Sealed Air Corporation (NYSE: SEE); and, STERIS Corporation (NYSE: STE).

Dr. Kosecoff holds a BA from the University of California, Los Angeles (UCLA), an MS in Applied Mathematics from Brown University, and a doctorate from UCLA.



Ernie Strapazon

Board Member

Mr. Strapazon has been involved with nutrition, health and wellness products for over thirty years. Most of this experience was with Nestlé where he held a variety of positions including brand management, global strategic planning, innovation/renovation and general management. He led a pioneering effort to establish the Nestlé Infant Nutrition business in the US.

As President, Nutritional Products Division and Nestlé Nutrition – USA, his responsibilities included Clinical Nutrition (Peptamen, Carnation Instant Breakfast) , Performance Nutrition (PowerBar) and Infant Nutrition (Good Start Infant Formulas).

Mr. Strapazon is also a board member of Nellson Nutraceutical, LLC. He holds an undergraduate degree in Chemistry from Northwestern University and a PhD in Biochemistry and MBA from the University of Chicago.


Martin P. Sutter

Board Member

Marty Sutter is Founder and Managing Director of EW Healthcare Partners. Educated in chemical engineering and finance, Mr. Sutter has more than 30 years of management experience in operations, marketing, finance and venture capital.

Mr. Sutter has been directly involved with more than 30 of EW Healthcare Partners’ portfolio investments, and has served on numerous past Boards of Directors of public and private companies including ATS Medical which was acquired by Medtronic, Inc., BioForm Medical which was acquired by Merz GmbH & Co KGaA, Lifecell which was acquired by Kinetic Concepts, Inc., St. Francis Medical which was acquired by Kyphon, Inc./Medtronic, Inc., Confluent Surgical which was acquired by Tyco International/Covidien and Rinat Neurosciences which was acquired by Pfizer, Inc. He currently serves on the Board of Directors of Abiomed Inc., Bioventus LLC, and Xenex Disinfection Services.

Mr. Sutter holds a Bachelor of Science degree from Louisiana State University, and a Master of Business Administration from the University of Houston.

Follow Us!